SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors.
about
State of play and clinical prospects of antibody gene transfer.Is immunity in cancer the key to improving clinical outcome?: Report on the International Symposium on Immunotherapy, The Royal Society, London, UK, 12-13 May 2017.Current Strategies to Enhance Anti-Tumour Immunity.Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial.Trial watch: DNA-based vaccines for oncological indications
P2860
SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
SCIB1, a huIgG1 antibody DNA v ...... of poorly immunogenic tumors.
@en
type
label
SCIB1, a huIgG1 antibody DNA v ...... of poorly immunogenic tumors.
@en
prefLabel
SCIB1, a huIgG1 antibody DNA v ...... of poorly immunogenic tumors.
@en
P2093
P2860
P356
P1433
P1476
SCIB1, a huIgG1 antibody DNA v ...... of poorly immunogenic tumors.
@en
P2093
Hideo Yagita
Lindy G Durrant
Peter Symonds
Rachael L Metheringham
Victoria A Brentville
P2860
P304
83088-83100
P356
10.18632/ONCOTARGET.13070
P407
P577
2016-11-04T00:00:00Z